Lactoferricin-Derived Peptides Successfully Kill Melanoma Cells From a Pregnant Patient, Offering a Potential Safer Treatment Option

A lymph node metastasis was obtained from a pregnant melanoma patient. Pigmented and non-pigmented sections were cultured under different laboratory conditions, yielding four distinct cell lines. Each line was comprehensively characterized for phenotypic properties, genetic mutations, and tumor-forming ability (including xenograft models in mice). Synthetic lactoferricin-derived peptides were then tested for anti-tumor effectiveness against all four lines.

Melanoma is one of the most common cancers diagnosed during pregnancy, and treatment options are severely limited by the need to protect the fetus. Anti-tumor peptides derived from lactoferricin — a natural component of breast milk — could provide a fundamentally different treatment approach with potentially better safety profiles for pregnant patients. Additionally, the four heterogeneous cell lines serve as a valuable research model for studying melanoma diversity and drug resistance.

This study connects two important research frontiers: anti-tumor peptide therapeutics and cancer treatment during pregnancy. Lactoferricin-derived peptides belong to a growing class of antimicrobial and anticancer peptides that selectively target tumor cells while potentially sparing normal tissue. The development of pregnancy-relevant cancer models also fills a critical gap, as pregnant patients are routinely excluded from clinical trials.

This is entirely a laboratory study — peptide effectiveness was demonstrated in cell culture and mouse xenografts, not in pregnant humans or animals. The safety of lactoferricin-derived peptides during pregnancy has not been tested. All four cell lines came from a single patient's tumor, which may not represent the full spectrum of melanoma diversity. The study does not compare peptide efficacy to standard melanoma therapies.